The stock of Aurobindo Pharma surged almost 7 per cent and touched its two-month high last Thursday. This was thanks to the company receiving final approval from the US Food & Drug Administration to make Sevelamer Carbonate oral suspension, a generic version of Genzyme’s Renvela oral suspension, prescribed for patients with chronic kidney disease. The approved product has an estimated ma...